Allos Therapeutics (ALTH) Announces Strong Data Related to PROPEL Trial of FOLOTYN In Patients with PTCL
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported new analyses of data from the Company’s pivotal PROPEL ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
